Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: A marker of ER-positive luminal-like subtype
Breast Cancer Research and Treatment, Volume 128, No. 2, Year 2011
Notification
URL copied to clipboard!
Description
Global gene expression profiling studies have classified breast cancer into a number of distinct biological and molecular classes with clinical relevance. The heterogeneous luminal group, which is largely characterised by oestrogen receptor (ER) expression, appears to contain distinct subgroups with differing behaviour. In this study, we analysed 47,293 gene transcripts in 128 invasive breast carcinomas (BC) using Artificial Neural Networks and a cross-validation analysis in combination with an ensemble sample classification to identify genes that can be used to subclassify ER+ luminal tumours. The results were validated using immunohistochemistry on TMAs containing 1,140 invasive breast cancers. Our results showed that the RERG gene is one of the highest ranked genes to differentiate between ER+ luminal-like and ER- non-luminal cancers based on a 10-fold external cross-validation analysis with an average classification accuracy of 89%. This was confirmed in our protein expression studies that showed RERG positive associations with markers of luminal differentiation including ER, luminal cytokeratins (CK19, CK18 and CK7/8) and FOXA1 (P = 0.004) and other markers of good prognosis in BC including small size, lower histologic grade and positive expression of androgen receptor, nuclear BRCA1, FHIT and cell cycle inhibitors p27 and p21. RERG expression was inversely associated with the proliferation marker MIB1 (P = 0.005) and p53. Strong RERG expression showed an association with longer breast cancer specific survival and distant metastasis free interval in the whole series as well as in the ER+ luminal group and these associations were independent of other prognostic variables. In conclusion, we used novel bioinformatics methods to identify candidate genes to characterise ER+ luminal-like breast cancer. RERG gene is a key marker of the luminal BC class and can be used to separate distinct prognostic subgroups. © 2010 Springer Science+Business Media, LLC.
Authors & Co-Authors
Habashy, Hany Onsy
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Egypt, Mansoura
Faculty of Medicine
Powe, Desmond George
United Kingdom, Nottingham
Queen's Medical Centre
Glaab, Enrico
United Kingdom, Nottingham
University of Nottingham
Ball, Graham Roy
United Kingdom, Nottingham
Nottingham Trent University
Spiteri, Inmaculada
United Kingdom, Cambridge
University of Cambridge
Krasnogor, Natalio
United Kingdom, Nottingham
University of Nottingham
Garibaldi, Jonathan M.
United Kingdom, Nottingham
University of Nottingham
Rakha, Emad A.
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Green, Andew R.
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Caldas, Carlos
United Kingdom, Cambridge
University of Cambridge
Ellis, Ian O.
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
United Kingdom, Nottingham
University of Nottingham
Statistics
Citations: 49
Authors: 11
Affiliations: 6
Identifiers
Doi:
10.1007/s10549-010-1073-y
ISSN:
01676806
e-ISSN:
15737217
Research Areas
Cancer
Genetics And Genomics